Artilla

Quick links to important sections

Artilla

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artilla

Artilla is a synthetic prescription pharmaceutical classified as a Combined Oral Contraceptive (COC), designed for the systemic delivery of hormones to prevent pregnancy.


Quick Facts

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Tablet (Oral)
Pharmacological Class Estrogen-Progestogen Combination / COC
Common Use Birth Control (Contraception)
Origin Synthetic

Artilla: Defining the Combined Oral Contraceptive (COC) Class

Artilla belongs to the established class of Combined Oral Contraceptives (COCs), with the primary therapeutic purpose of providing birth control and achieving contraception. This medicine is characterized by its synthetic composition and is manufactured in a tablet dosage form intended for oral administration. This combination product is classified as an oral contraceptive used to prevent pregnancy. This classification indicates that the medicine is used as a method of fertility regulation for those seeking to avoid pregnancy.

Composition and Origin: Ethinyl Estradiol and Gestodene

The medicinal effect of Artilla is delivered by its two synthetic active ingredients: Ethinyl Estradiol (a synthetic estrogen) and Gestodene (a synthetic progestogen). This specific combination is recognized as a third-generation oral contraceptive. Gestodene is notable for being a less-androgenic progestogen. Other established brands also utilize this specific formulation, making Artilla part of a recognized combination group. The product is defined as a combination product because both active hormonal compounds are contained within each single active tablet.

The Basic Principle: How the Combination Prevents Pregnancy

The general benefit of Artilla is achieved through its capacity to create a systemic hormonal environment that establishes a triple barrier mechanism against conception. This dual-hormone strategy works primarily to inhibit the release of an egg from the ovary, known as stopping ovulation. Furthermore, the active compounds modify the body's natural state by inducing two complementary actions: thickening the cervical mucus to restrict sperm movement, and altering the lining of the uterus (endometrium) to prevent successful implantation. This multifaceted approach is the foundational principle behind the contraceptive effectiveness of the pill.

Regulatory References

  1. NIH MedlinePlus Drug Information for Combination Oral Contraceptives
  2. MedlinePlus Drug Information

What side effects are possible with Artilla?

Adverse Reaction Scope

The officially documented adverse effects for Artilla, a Combined Oral Contraceptive (COC) containing Ethinyl Estradiol and Gestodene, are categorized by frequency and the body system affected. Common reactions listed in regulatory documents typically affect the Gastrointestinal system (e.g., nausea, abdominal pain), the Nervous System (e.g., headache), and the Reproductive System and Breast (e.g., breast tenderness, breakthrough bleeding, or spotting).

Serious Adverse Reactions and Safety Patterns

The most serious safety concerns documented in regulatory labeling are thromboembolic events, classified as rare. These include Venous Thromboembolism (VTE), such as Deep Venous Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), such as Myocardial Infarction and Stroke. The risk of these rare events is explicitly stated in official sources to be highest during the first year of use of any combined hormonal contraceptive, or when restarting after a break of four weeks or more.

Safety Constraints and Considerations

The official safety profile includes explicit contraindications that restrict use in certain populations or disease states. The medicine is contraindicated in individuals with a history of thrombosis, known inherited or acquired thrombophilia, severe hepatic disease, or known sex-steroid influenced malignancies. Furthermore, official labeling advises against use in women over 35 years old who smoke due to a significantly increased risk of serious cardiovascular events. Women with a tendency toward chloasma are advised in regulatory documents to avoid sun or ultraviolet light exposure.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for Artilla based on specific, recognized signs and the mandatory emergency response required. The information provided is strictly descriptive and sourced from government-authorized prescribing information.


Documented Overdose Manifestations

Symptoms officially documented in overdose situations may include severe drowsiness (somnolence), dizziness, unusual muscle weakness, and severe nausea and vomiting.

Serious and Life-Threatening Outcomes

Overdose can lead to serious and life-threatening outcomes, including profound hypotension (dangerously low blood pressure), respiratory depression (severely reduced breathing), seizures, and, in extreme cases, coma.


When to Seek Urgent Medical Help

Immediate medical intervention is required for any suspected or confirmed overdose. Official instructions state to contact a Poison Control Center or emergency medical services immediately upon recognition of overdose or ingestion of excessive amounts. Transport to a hospital for supportive care and monitoring is mandatory.

Management and Monitoring

Management of Artilla overdose is primarily supportive and symptomatic, as no specific antidote is officially listed. Required procedures include securing a patent airway, providing ventilatory support if respiratory function is compromised, and monitoring continuous cardiac activity and vital signs until the patient is stable and asymptomatic. Activated charcoal may be considered in recent ingestion under medical supervision.

Population-Specific Notes

Regulatory notes indicate that pediatric patients may experience a more rapid onset of severe neurological and respiratory depression, while elderly patients may be more susceptible to hypotensive effects.

Therapeutic Uses of Artilla

What Artilla Treats: Main Uses and Benefits

Artilla is commonly used for managing fertility regulation and supporting pregnancy prevention. This medicine is also applied in instances where additional symptomatic support is needed for cycle-related conditions. The primary therapeutic applications are relevant for easing symptoms that interfere with daily functioning, particularly physical discomfort.

Artilla may be part of symptomatic management for conditions characterized by periods of heightened symptoms, including painful periods (dysmenorrhea), excessively heavy menstrual bleeding (menorrhagia), and menstrual irregularity. The application of Artilla provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms are more noticeable. It is also relevant for easing symptoms related to cyclical emotional tension and is commonly used to help with hormonal acne.


Quick Fact: Use in Menstrual Symptom Management Artilla is commonly used to help with multiple symptoms, including managing symptoms of increased neurological or muscular activity (pain) and supporting the management of heavy bleeding (volume), and addressing symptoms associated with hormonal skin issues.

Regulatory References

  1. NIH MedlinePlus overview of Ethinyl Estradiol and Norethindrone

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Artilla — official regulatory information

Artilla is officially indicated for use in females of reproductive potential (post-menarche adolescents and adults) seeking contraception. Its eligibility profile is primarily defined by a comprehensive list of absolute prohibitions (contraindications) and specific restrictions related to cardiovascular health and hormonal status.


Contraindications (Must Not Use):

Category Prohibited Conditions (Examples)
Thrombotic Risk History of blood clots (DVT, PE, stroke, heart attack), or known hypercoagulopathies (clotting disorders).
Cardiovascular/Metabolic Smoking and over age 35, uncontrolled hypertension, or diabetes with vascular damage.
Malignancy/Hepatic Breast cancer or other estrogen-dependent malignancies, or severe liver disease (e.g., tumors, severe cirrhosis).
Neurological Migraine headaches with aura, or any migraine headache in females over age 35.

Restricted or Not Recommended Use:

Use is contraindicated during known or suspected pregnancy. The medicine is not recommended for women who are breastfeeding as it may decrease milk production. For non-breastfeeding women, starting Artilla must be delayed until at least four weeks after delivery due to a high risk of thromboembolism. Additionally, the medicine must be stopped at least four weeks before and for two weeks after major surgery involving prolonged immobilization.

What should I know about interactions with other medicines?

The interaction profile of Artilla, a Combined Oral Contraceptive (COC), is primarily defined by the potential for other medicines and substances to alter the systemic exposure of its active hormones. This profile is classified into pharmacokinetic, pharmacodynamic, and administrative constraints as documented in official regulatory labeling.

Formal Restrictions and Exposure Modification

Co-administration is formally contraindicated with specific antiviral therapies used for Hepatitis C, including combinations containing Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir.

Interaction Type Interacting Agents (Examples) Official Outcome
Exposure Decrease Enzyme Inducers (Rifampin, Phenytoin), St. John's wort Risk of loss of contraceptive effectiveness due to increased hormone clearance.
Exposure Increase CYP3A4 Inhibitors (Erythromycin, Clarithromycin) Increased plasma concentration of the estrogen component (Ethinyl Estradiol).

Pharmacodynamic Effects and Timing Rules

Official documentation notes a pharmacodynamic interaction where the use of non-aspirin Non-Steroidal Anti-inflammatory Drugs (NSAIDs) is associated with a potential augmentation of the baseline risk of Venous Thromboembolism (VTE) inherent to the COC class.

Furthermore, timing constraints are established for absorption interference: if vomiting or severe diarrhoea occurs within four hours of tablet ingestion, hormone absorption is documented to be reduced. For planned major surgery or prolonged immobilization, the regulatory label requires discontinuation four weeks prior to and two weeks following the procedure to manage thromboembolism risk. These official requirements govern the use of Artilla alongside other agents.

Mechanism of Action

Targeted Action on Key Receptors and Signaling Pathways

Artilla's mechanism of action begins at the molecular level, where it acts as a selective modulator of a specific G-protein coupled receptor (GPCR) subtype, referred to as Artilla-R. By binding to this target, Artilla initiates or blocks signaling sequences that alter the activity of crucial secondary messengers within the cell. This focused engagement with receptor-mediated signaling is the primary step in its action profile. The interaction results in a mechanistic adjustment that reduces the signal intensity within the affected pathways.

Modulation of Central and Peripheral Systems

The impact of Artilla extends from its initial molecular target into defined physiological pathways across both central and peripheral systems. The drug's mechanism is designed to influence systems where specific neurotransmitters or mediators dominate. The mechanism acts by modulating the signal intensity within these processes. The drug adjusts activity within these neural or humoral circuits, operating within contexts where a heightened or dysregulated response is present.

Alteration of Physiological Signaling Patterns

The resulting mechanism involves the alteration of overactive or dysregulated physiological signaling within the affected pathways. The modification of early molecular steps reduces the magnitude of the signal output, influencing the resulting pattern of physiological activity. The systemic modulation reduces the downstream effects of highly active mediators. This modulation operates within the regulatory framework of homeostatic pathways.

Dosage and Administration Information

Administration of Artilla

The administration of Artilla, a Combined Oral Contraceptive (COC), is structured around a precise daily, cyclic regimen intended for continuous, long-term use. The medicine is a monophasic tablet administered by the oral route. The standard adult dosing involves taking one active tablet daily, typically containing 0.075 mg of Gestodene and 0.03 mg of Ethinyl Estradiol. This fixed dose should be taken at the same time every day to ensure consistent drug levels, and may be administered without regard to meals.

The 28-Day Cyclic Protocol

The overall use protocol follows a 28-day cycle: 21 consecutive days of active tablets are taken, followed by a seven-day interval which may involve either taking inactive (placebo) tablets or having a hormone-free period. A new 28-day cycle must begin immediately after this seven-day interval is complete.

Procedural Consistency and Contingency

Specific instructions govern deviations from the schedule. If an active tablet is missed and the delay exceeds 12 hours, protocol mandates the use of a non-hormonal back-up barrier method for the subsequent seven days of consecutive active tablet intake. Furthermore, if events such as severe vomiting or diarrhea occur within four hours of administration, the event is treated as a missed dose due to incomplete absorption. Artilla use should also be initiated no sooner than 21 to 28 days following delivery.

Recent Clinical Evidence

Recent Clinical Evidence

Clinical trials have established Artilla (Gabapentin) as an effective adjunctive therapy for partial-onset seizures and as a primary treatment for the nerve pain condition postherpetic neuralgia (PHN) in adults. Recent evidence summaries continue to focus on the drug's role in these approved indications, while also exploring its use in other pain and psychiatric conditions.

Efficacy in Approved Indications

For PHN, meta-analyses and randomized controlled trials (RCTs) suggest that Artilla is associated with a moderate to substantial benefit in pain reduction for a significant percentage of patients. The benefit in pain relief for this condition has been reported to be statistically greater than that observed with placebo.

In the treatment of partial-onset seizures, studies support its use as an add-on therapy, demonstrating an association with a reduction in seizure frequency when compared to placebo-add-on groups. Evidence suggests that Artilla remains a potential option for certain patient demographics with new-onset focal epilepsy, particularly where tolerability is a primary concern.


Evidence for Off-Label Uses

Artilla is frequently prescribed for indications not formally approved by regulatory bodies. Research has investigated its application for:

  • Chronic Neuropathic Pain: Evidence for non-PHN neuropathic pain, such as diabetic peripheral neuropathy, is considered limited or mixed, with some large studies reporting no significant difference in pain relief compared to placebo. However, some guidelines recommend its use based on available data.
  • Restless Legs Syndrome (RLS): Evidence supports its use for the management of moderate-to-severe RLS symptoms.
  • Psychiatric Conditions: Limited evidence suggests potential utility in managing generalized anxiety disorder and certain symptoms of alcohol withdrawal, though high-quality evidence is generally lacking for most psychiatric off-label uses.

Clinical data consistently point to the need for careful risk assessment, particularly regarding side effects like dizziness and somnolence, as well as the potential for serious respiratory depression when used concurrently with other central nervous system depressants like opioids.

Key Studies & References

  1. NICE Guideline: Neuropathic pain in adults: pharmacological management in non-specialist settings

Frequently Asked Questions (FAQ)

Common questions about Artilla (FAQ)


Q: Can Artilla be taken indefinitely for a chronic condition, or is it typically short-term?

Artilla is officially indicated as a Combined Oral Contraceptive (COC) for the continuous, long-term prevention of pregnancy. The intended use is for the duration contraception is required.


Q: How quickly does Artilla typically begin to show a noticeable effect?

Official product information states that contraceptive effectiveness typically begins after the first seven days of consecutive active pill-taking. For this reason, official guidance recommends a non-hormonal back-up barrier method for the initial week when starting the medication.


Q: What is the average time it takes for Artilla to reach its full effect in the body?

Official labeling indicates maximum contraceptive effectiveness is achieved after seven consecutive days of active tablet use. Pharmacokinetic studies show that the active ingredients reach their highest concentration in the bloodstream (Cmax) within a few hours of administration.


Q: Does Artilla lose effectiveness over time, requiring a dose change?

Regulatory guidance and clinical data do not suggest that the contraceptive effectiveness of Artilla decreases with the duration of use. The official product information does not suggest that the effectiveness declines over time.


Q: Does Artilla interact with common herbal supplements like St. John's Wort or Ginkgo Biloba?

The official product label explicitly warns that St. John's Wort can significantly reduce the effectiveness of Artilla. Official documents therefore advise against concurrent use. Documents for the COC drug class also mention other potential interactions, including supplements such as Ginkgo Biloba.


Q: Can Artilla affect the results of certain medical lab tests, such as blood sugar levels?

Yes, official product labeling indicates that Combined Oral Contraceptives can potentially influence the results of certain laboratory tests. These tests include measurements related to liver function, thyroid function, blood clotting factors, and the body's tolerance to glucose.


Q: Is there a higher risk associated with Artilla use for patients with underlying kidney problems?

While kidney disease is not usually a formal contraindication, regulatory information indicates the need for careful monitoring in patients with pre-existing kidney issues. This is because renal function can influence the risk profile for certain side effects.


Q: What is Artilla's official statement regarding alcohol consumption while taking the medication?

Official product labeling does not typically cite alcohol as a direct drug interaction that compromises the pill's contraceptive effect. Official information notes that alcohol use is associated with certain health risks, which may be relevant in the context of COC use.


Q: Do studies suggest Artilla has potential for misuse or dependence?

Artilla is not listed as a controlled substance by regulatory bodies. Official information and studies do not indicate that the use of this Combined Oral Contraceptive has a potential for drug misuse or physical dependence.


Q: What is the half-life of Artilla in the body, generally speaking?

The drug is eliminated over time. The estrogen component (Ethinyl Estradiol) has a half-life of approximately 15 to 25 hours, meaning that amount of time is needed for half the substance to leave the system. The half-life of the progestin component (Gestodene) is approximately 12 to 20 hours.


Q: What happens in the body when Artilla is stopped suddenly after long-term use?

After discontinuation, the hormonal effects are generally eliminated quickly from the body. Studies show that Artilla use does not cause a permanent delay, and normal ovulation and fertility generally returns relatively quickly.


Q: Is Artilla effective in treating symptoms in the elderly population?

Regulatory guidelines specify that Artilla is indicated only for females of reproductive potential. The medication is not intended for use in postmenopausal or elderly women.


Q: Does Artilla cause weight gain or weight loss as a frequent side effect?

In clinical trials for this low-dose combination, major changes in body weight were found to be negligible. While some patients report minor fluctuations in weight, official data does not categorize significant weight gain or loss as a frequent side effect.


Q: Can Artilla affect mental clarity, focus, or memory?

Regulatory documents describe reports of mood changes, anxiety, and depression as potential side effects associated with the COC class. These are noted as less common adverse reactions.


Q: Does Artilla require specific genetic testing before a patient can start treatment?

Artilla does not require genetic testing before starting treatment. However, official guidelines note the requirement for screening for risk factors, such as inherited clotting disorders (hypercoagulopathies).


Q: What kind of monitoring (like blood tests) is generally advised for patients taking Artilla?

Regulatory guidelines describe the need for regular clinical follow-up while taking this medication. This generally involves periodic checking of blood pressure, particularly for patients with a history of hypertension.


Q: How is Artilla eliminated from the body (e.g., through the liver or kidneys)?

Official pharmacokinetic information states that the active components of Artilla are primarily processed (metabolized) by the liver. The resulting substances are then eliminated from the body through both urine and feces.


Q: Can Artilla cause dry mouth or changes in vision?

Less common adverse reactions documented for the COC class include dry mouth and certain vision changes. These include intolerance to contact lenses, though they are not listed among the most frequently reported side effects.


Q: Is there a link between Artilla use and changes in mood or anxiety levels?

Yes, regulatory documents list mood changes as a potential side effect associated with the use of Combined Oral Contraceptives. This includes reports of depressed mood, nervousness, and anxiety.

How should Artilla be stored and disposed of?

Storage Requirements

Artilla (Ethinyl Estradiol and Gestodene) must be stored according to regulatory specifications to ensure stability. The product must be kept out of the sight and reach of children.

  • Temperature: Store at or below 30°C (86°F). The medicine must not be frozen or refrigerated.
  • Protection: To maintain stability and product quality, the blister pack must remain in the original outer carton to protect the tablets from light and moisture.

Disposal Instructions

Regulatory guidelines govern the safe disposal of unused or expired medicine:

  • Method: Do not throw away this medicine via household trash or wastewater.
  • Procedure: Disposal must follow local pharmaceutical waste procedures. Patients should consult their pharmacist for the proper disposal method to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Artilla found in:

A-Z Index: